Cathie Wood Just This Biotech Bet: Reading the Signals
ARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
Target discretionary areas first, compare frequent bills, and negotiate rates to reduce outflows while maintaining needs.
14,378 articlesARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
AI is changing how businesses operate and scale. This guide highlights three top here artificial intelligence stocks ...
In a year of sharp rotation, the Vanguard FTSE DEVELOPED Markets ETF ex US is outperforming the S&P 500—yet the decad...
When healthcare stocks rally, two ETFs often surface as popular bets: Vanguard Health Care (VHT) and Invesco Pharmace...
Amazon shocks privacy watchers by ending its partnership with Flock Safety after a controversial Super Bowl ad. The m...
ImmunityBio has grabbed headlines as shares surge amid regulatory wins and pipeline potential. This deep dive explain...
Rivian is plotting a bold three-year arc that hinges on scale, software, and partnerships. This guide breaks down the...
A pivotal license extension in Ghana fuels a surge in Kosmos Energy. This article breaks down what the move means for...
When conviction runs hot but capital is capped, traditional 1:1 bets may feel limiting. The forget returns: double-le...
Uber's top executive forecasts a future where autonomous taxis handle the bulk of trips within two decades, a scenari...
A clear, practical look at Bowhead Specialty's Q4 2025 earnings transcript. Learn what the numbers mean, which metric...
As Rocket Lab nears a pivotal earnings print, investors are quietly growing more bullish. This piece breaks down why ...